- Noteworthy events during the week of November 25 - December 1 for healthcare investors.
- MONDAY (11/26): FDA action date for Loxo Oncology's (NASDAQ:LOXO) larotrectinib in NTRK fusion-positive solid tumors.
- Genocea Biosciences (NASDAQ:GNCA): KOL event on personalized cancer immunotherapies, NYC.
- WEDNESDAY (11/28): FDA action date for Catalyst Pharmaceuticals ' (NASDAQ:CPRX) Firdapse for LEMS and Astellas Pharma's (OTCPK:ALPMF) gilteritinib for FLT3-positive AML.
- THURSDAY (11/29): American Epilepsy Society Annual Meeting, New Orleans (6 days). Marinus Pharmaceuticals (NASDAQ:MRNS): Data on ganaxolone in children with CDKL5 Deficiency Disorder and PCDH19-related epilepsy. GW Pharmaceuticals (NASDAQ:GWPH): Phase 3 Epiolex data, preclinical and Phase 1 cannabidiol data.
- SATURDAY (12/1): American Society of Hematology (ASH) Annual Meeting, San Diego (4 days). Argenx (NASDAQ:ARGX): Phase 2 data on efgartimod in primary immune thrombocytopenia. TG Therapeutics (NASDAQ:TGTX): Updated data on U2. Sierra Oncology (NASDAQ:SRRA): Momelotinib data. Sunesis Pharmaceuticals (NASDAQ:SNSS): Vecabrutinib data. Atara Biotherapeutics (NASDAQ:ATRA): Off-the-shelf CAR-T therapies. MiRagen Therapeutics (NASDAQ:MGEN): Phase 1 data on cobomarsen. Bio-Path Holdings (NASDAQ:BPTH): Phase 2 data on BP1001 (prexigebersen). Acceleron Pharma (NASDAQ:XLRN): Phase 3 data on luspatercept in MDS and beta-thalassemia. Affimed (NASDAQ:AFMD): Six abstracts. Verastem Oncology (NASDAQ:VSTM): Eight abstracts. Daiichi Sankyo (OTCPK:DSKYF): Phase 1 data on valemetostat, Phase 3 data on quizartinib preclinical data in quizartinib + milademetan. Bluebird bio (NASDAQ:BLUE): Phase 3 data on lentiglobin in beta-thalassemia, Phase 1 data on lentiglobin in SCD, Phase 1 data on bb21217 in MM, Phase 1 data on BCL11a shRNAmiR in SCD. Allogene Therapeutics (NASDAQ:ALLO): Pipeline data. Global Blood Therapeutics (NASDAQ:GBT): Four abstracts in SCD, including voxelotor. Unum Therapeutics (NASDAQ:UMRX): Phase 1 data on ACTR707 (with rituximab) in CD20+ B cell lymphomas. Celgene (NASDAQ:CELG): More than 100 abstracts. GlycoMimetics (NASDAQ:GLYC): Phase 1/2 data on uproliselan + chemo in AML. NewLink Genetics (NASDAQ:NLNK): Phase 1 data on indoximod in AML. Xencor (NASDAQ:XNCR): Phase 1 data on XmAb 14045 in AML. ImmunoGen (NASDAQ:IMGN): IMGN779 and IMGN632 data. Celyad (NASDAQ:CYAD): Phase 1 data on CYAD-01 in AML. Fate Therapeutics (NASDAQ:FATE): Preclinical data on FT500, Phase 1 data on ProTmune, introduce FATE-NK100. Bellicum Pharmaceuticals (NASDAQ:BLCM): Eight abstracts on lead candidate rivo-cel (BPX-501). Magenta Therapeutics (NASDAQ:MGTA): Five abstracts on ADCs, Phase 2 data on MGTA-456. Actinium Pharmaceuticals (NYSEMKT:ATNM): Multiple abstracts on antibody-radiation conjugates, Phase 3 data on Iomab-B. Roche (OTCQX:RHHBY): Over 70 abstracts. Stemline Therapeutics (NASDAQ:STML): Four abstracts on Elzonris (tagraxofusp)(SL-401). Humanigen (OTCQB:HGEN): Preclinical data on lenzilumab + CART19 for preventing CRS. Novartis (NYSE:NVS): Multiple abstracts, update on Kymriah in DLBCL. Seattle Genetics (NASDAQ:SGEN): Phase 3 data on Adcetris in first-line CD30+ peripheral T-cell lymphoma. MorphoSys (NASDAQ:MOR): Phase 2 data on MOR208 and Phase 1/2a data on MOR202. ArQule (NASDAQ:ARQL): Phase 1 data on ARQ 531.
- Now read: Erytech Pharma S.A. ADS 2018 Q3 - Results - Earnings Call Slides
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Original article